Hoffmann-la Roche

This study tested a monthly injection called Mircera in 75 adults with chronic kidney disease and anemia who were not yet on dialysis. The goal was to see if the shot could safely raise and maintain healthy red blood cell levels. Participants received one shot each month for up t…

This study tested a combination of two immunotherapy drugs (atezolizumab and tiragolumab) against a placebo plus one drug for people with advanced head and neck cancer that had come back or spread. The goal was to see if the two-drug combo could shrink tumors better. 123 adults w…

This study tested a new combination of drugs (venetoclax and obinutuzumab) against standard chemotherapy (FCR or BR) in 166 fit patients with previously untreated chronic lymphocytic leukemia (CLL) who did not have certain genetic mutations. The goal was to see if the new combo c…

This study tested two different drug combinations in 445 people with untreated chronic lymphocytic leukemia (CLL) who also had other medical conditions. One group received obinutuzumab plus venetoclax, the other obinutuzumab plus chlorambucil. The main goal was to see which combi…

This study tested a new drug called RO7247669 in 93 people with advanced melanoma that could not be removed by surgery or had spread. The goal was to see if the drug could control the cancer and to find the best dose. Participants received one of two dose levels, and researchers …

This study tested several immunotherapy-based drug combinations in 272 people with advanced bladder cancer that had worsened after standard platinum chemotherapy. The goal was to see if these combinations could shrink tumors or stop cancer growth. The flexible 'umbrella' design a…

This study tested a new combination of two immunotherapy drugs (tiragolumab and atezolizumab) given together as a single injection. The goal was to see if this fixed-dose combo is safe and how it works in the body for people with advanced solid tumors that have a specific marker …

This early-stage study tested a new drug, glofitamab, combined with standard chemotherapy (R-ICE) in 43 people with diffuse large B-cell lymphoma that returned or didn't respond to initial treatment. Participants were healthy enough to be candidates for a stem cell transplant or …

This study followed 1710 people with multiple sclerosis (MS) who were prescribed ocrelizumab as part of their normal care. Researchers tracked changes in symptoms like fatigue, hand function, and thinking skills, as well as side effects. The goal was to see how well the drug work…

This study tested whether adding the immunotherapy drug atezolizumab to standard chemotherapy before surgery helps people with stage II to IIIB non-small cell lung cancer live longer without the cancer coming back. About 453 adults with resectable tumors took part. The approach a…

This study tested whether adding the experimental drug tiragolumab to a standard treatment (atezolizumab plus chemotherapy) helps people with untreated extensive-stage small cell lung cancer live longer or delay cancer growth. About 490 participants were randomly assigned to rece…

This study looked at different combinations of immunotherapy drugs in 314 people with advanced non-small cell lung cancer. Some participants had not been treated before, while others had already tried chemotherapy and immunotherapy. The goal was to see if these new combos could s…

This study looked at the long-term safety of the drug tocilizumab (RoActemra/Actemra) in children with a type of arthritis called polyarticular-course juvenile idiopathic arthritis. Seven children who had already completed a previous study received the drug every 4 weeks for up t…

This study tested whether adding tiragolumab to atezolizumab (both immunotherapy drugs) works better than atezolizumab alone for people with non-small cell lung cancer who had surgery and chemotherapy. The trial enrolled 56 adults with stage IIB to IIIB PD-L1 positive cancer. The…

This study tested a drug called TRO19622 in 22 adults with NASH, a type of fatty liver disease. Participants took either the drug or a placebo daily for one month to see if it safely lowered liver enzymes. The goal was to check short-term safety and effects on the liver, not to c…

This study tested a medicine called emicizumab in 73 people with mild or moderate hemophilia A (a blood clotting disorder). Participants received regular injections to see if it could safely reduce bleeding episodes. The results showed fewer bleeds compared to before treatment, o…

This study observed 178 Chinese patients with HER2-positive advanced breast cancer who received T-DM1 as a second or later treatment. Researchers tracked side effects and how long the drug kept the cancer from growing in everyday medical practice. The goal was to confirm the drug…

This study tested whether adding a new drug (tiragolumab) to a standard immunotherapy combination works better than the current standard treatment for people with advanced non-squamous lung cancer who haven't had treatment before. About 542 participants received either the new co…

This study tested an experimental drug called vamikibart, given as an eye injection, for people with uveitic macular edema — swelling in the back of the eye caused by inflammation. The trial involved 256 adults and measured whether the treatment improved vision and reduced swelli…

This study tested if a shot (subcutaneous) of the immunotherapy drug atezolizumab works as well as the standard IV drip for people with advanced non-small cell lung cancer. About 438 patients who had already tried platinum-based chemotherapy took part. The goal was to see if the …

This study tested several immunotherapy-based drug combinations in 144 people with advanced hormone receptor-positive, HER2-negative breast cancer that had worsened after standard treatment. The goal was to see if these combinations could shrink tumors or slow the cancer's growth…

This study tested a combination of two drugs (atezolizumab and cabozantinib) against a standard chemotherapy (docetaxel) in 366 people with advanced non-small cell lung cancer that had worsened after prior treatments. The goal was to see if the combination helped people live long…

This study tested an investigational drug called vamikibart (RO7200220) for people with diabetic macular edema, a condition where fluid builds up in the eye and blurs vision. About 394 participants received injections into the eye to see if the drug could improve vision and reduc…

This study looked at 322 adults with moderate-to-severe rheumatoid arthritis who were starting treatment with tocilizumab (RoActemra/Actemra). Researchers tracked their disease activity for 12 months to see how well the drug worked and how safe it was in real-world settings. The …

This study tested whether adding pertuzumab to the usual chemotherapy plus trastuzumab could better prevent breast cancer from returning in people with operable HER2-positive breast cancer. Over 4,800 participants were randomly assigned to receive either the extra drug or a place…

This study tested whether adding the drug polatuzumab vedotin to a standard chemotherapy regimen (R-GEMOX) helps people with relapsed or refractory diffuse large B-cell lymphoma, a type of blood cancer that has returned or not responded to prior treatment. About 270 adults partic…

This study tested whether a once-monthly injection of Mircera works as well as the standard epoetin alfa treatment for managing anemia in people on dialysis. About 233 adults with chronic kidney disease and anemia took part. The goal was to see if the monthly shot could keep hemo…

This study tested a small, refillable implant placed in the eye that continuously releases medication to treat diabetic retinopathy, a leading cause of vision loss. 174 adults with moderate-to-severe diabetic retinopathy participated. The goal was to see if the implant could impr…

This early-phase study tested a new drug called eciskafusp alfa (RO7284755), alone or with another immunotherapy (atezolizumab), in 189 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the right dos…

This study looked at how safe and tolerable the drug risdiplam is for people with spinal muscular atrophy (SMA), a genetic disease that weakens muscles. It included 174 adults, children, and infants who had already tried other SMA treatments. Researchers monitored side effects an…

This study looked at how well and how safely the drug ocrelizumab works over a longer period for people with multiple sclerosis (MS). Over 1,000 participants who had already been in earlier Roche studies took part. The goal was to see if the drug could keep disability from gettin…

This study tested a new way to give two powerful breast cancer drugs (pertuzumab and trastuzumab) as a single shot under the skin instead of through an IV drip. It included 200 Chinese patients with HER2-positive early breast cancer. The goal was to see if the shot works as well …

This study looked at how well the drug MIRCERA controls anemia in 144 adults with moderate chronic kidney disease (stages 3-4) who are not yet on dialysis. Researchers tracked hemoglobin levels and safety over 12 months in real-world clinics. The goal was to see if patients reach…

This early-phase study tested a new drug called forimtamig in 225 people with multiple myeloma that had returned or not responded to treatment. Participants had already tried standard therapies and had few options left. The main goals were to check the drug's safety and find the …

This study tested several new drug combinations in 281 adults with chronic hepatitis B who already take standard antiviral medication. The goal was to see if these combinations could clear the hepatitis B surface antigen (HBsAg) from the blood, which is a sign of better disease c…

This study compared a single dose of baloxavir marboxil to a 5-day course of oseltamivir in 100 Chinese children aged 1 to 12 with flu symptoms. The main goal was to check safety, including side effects. Researchers also measured how quickly flu symptoms like cough and fever impr…

This study looked at whether people with early or locally advanced HER2-positive breast cancer prefer receiving their medication at home versus in the hospital. 346 participants were randomly assigned to receive treatment in both settings and then asked which they liked more. The…

This study looked at whether people with non-small cell lung cancer prefer getting the drug atezolizumab as a shot under the skin or through an IV. About 179 adults took part, including those with early-stage cancer after surgery and those with advanced cancer. The main goal was …

This study looked at how much of the multiple sclerosis (MS) drug ocrelizumab passes into breastmilk and whether it affects babies' immune cells (B cells). Twenty-six breastfeeding women with MS or clinically isolated syndrome (CIS) and their healthy infants took part. Researcher…

This study tested tumor tissue samples from 470 people with solid tumors to look for specific biomarkers. The goal was to see if those biomarkers made them eligible for other Roche clinical trials testing new treatments. Participants did not receive any treatment as part of this …

This study checked how much of the multiple sclerosis drug ocrelizumab passes from mother to baby during pregnancy. Researchers measured B cell levels in 70 infants whose mothers took the drug before or early in pregnancy. The goal was to understand the drug's effect on the baby'…